Tag: Rare Disease Genome Editing Market Growth

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Rare Disease Genome Editing Market Size And Revenue Outlook Through 2030

The market size for rare disease genome editing has experienced swift expansion recently. This market is projected to expand from $1.29 billion in 2025 to $1.51 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.8%. Historically, this growth can be ascribed to several factors including progress in gene editing technologies, a rise in the identification of rare genetic mutations, increased funding for genomic research, initial successes in gene therapy trials, and expanding academic research endeavors.

The rare disease genome editing market is anticipated to experience substantial growth in the coming years. It is forecast to expand to $2.88 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 17.5%. This growth throughout the forecast period can be attributed to several factors, including increased investment in curative rare disease therapies, a rising acceptance of precision medicine approaches, the expansion of clinical genome editing trials, growing regulatory support for orphan drugs, and increased collaboration between biotech companies and healthcare providers. Notable trends during this period are expected to encompass the increasing adoption of CRISPR-based therapeutics, a rising focus on gene editing for monogenic disorders, the growing utilization of personalized genome editing approaches, the expansion of advanced editing platforms, and enhanced integration of genomic data analytics.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=58085563&type=smp&name=Rare%20Disease%20Genome%20Editing%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Rare Disease Genome Editing Market Growth Catalysts And Demand Drivers

An escalating emphasis on precision medicine is anticipated to fuel the expansion of the rare disease genome editing market in the future. This tailored healthcare methodology leverages an individual’s genetic makeup, environmental factors, and lifestyle choices to deliver more precise and efficacious therapies. The heightened interest in precision medicine stems from progress in genomic sequencing and the identification of biomarkers, which facilitate accurate detection and the development of targeted treatments. The rare disease genome editing market plays a crucial role in advancing precision medicine by allowing for the specific correction of genetic mutations, thereby enhancing the personalization and efficacy of treatments. This technology improves healthcare by tackling the fundamental causes of rare conditions, leading to better patient results and a decreased dependence on managing symptoms alone. Illustratively, in March 2024, Novotech, an Australia-based biotechnology firm, reported that in 2023, out of 217 FDA-approved oncology treatments, 43% were precision oncology treatments, with 78 of these integrating DNA or NGS-detectable biomarkers. Consequently, the growing concentration on precision medicine is a key impetus for the expansion of the rare disease genome editing market.

Rare Disease Genome Editing Market Segment Outlook: Which Categories Are Growing Fastest?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

Rare Disease Genome Editing Market Trends Shaping Long-Term Demand

Leading companies within the rare disease genome editing market are prioritizing the development of advanced therapeutic platforms, specifically CRISPR-based gene editing systems. This focus aims to enhance treatment precision, improve therapeutic outcomes, and address genetic diseases previously considered incurable. CRISPR-based gene editing systems represent innovative technologies enabling precise modifications to the genome, thereby allowing for the correction of genetic defects or the introduction of therapeutic genes into cells. For example, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and obtained conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises, or those with transfusion-dependent beta thalassemia (TDT). CASGEVY functions by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which in turn reduces or eliminates disease symptoms and presents a potential functional cure for these conditions.

Rare Disease Genome Editing Market Leading Companies And Competitive Benchmarking

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

View The Full Rare Disease Genome Editing Market Report:

https://thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Rare Disease Genome Editing Market Regional Analysis: Which Geography Leads On Revenue?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Rare Disease Genome Editing Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for genome editing in rare diseases has undergone rapid expansion in recent years, with its value projected to increase from $1.29 billion in 2025 to $1.51 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.8%. This historic growth was driven by progress in gene editing tools, a greater number of rare genetic mutations being identified, increased funding allocated to genomic research, encouraging outcomes from early gene therapy clinical trials, and a rise in academic research programs.

The market for rare disease genome editing is set to experience substantial expansion in the near future, projected to reach a valuation of $2.88 billion by 2030 with a compound annual growth rate of 17.5%. This upward trajectory in the forecast period is driven by higher levels of investment directed toward curative therapies for rare conditions, a greater embrace of precision medicine techniques, a broadening scope of clinical trials involving genome editing, enhanced regulatory frameworks supporting orphan drug development, and strengthened partnerships between biotechnology firms and healthcare organizations. Key emerging trends shaping this period include a growing reliance on crispr-based treatments, an intensified emphasis on editing genes associated with monogenic disorders, a heightened application of customized genome editing strategies, the development of more sophisticated editing platforms, and a deeper integration of genomic data analysis tools.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Rare Disease Genome Editing Market Growth Drivers: What Factors Are Accelerating Expansion?

The rare disease genome editing market is anticipated to expand due to a growing emphasis on precision medicine. This approach to healthcare customizes treatments based on an individual’s genetic profile, environment, and lifestyle to enhance accuracy and effectiveness. Its rising prominence stems from progress in genomic sequencing and biomarker discovery, which facilitate precise diagnosis and targeted therapies. The genome editing market contributes to this field by enabling exact correction of genetic defects, thereby tailoring interventions to each patient. This method transforms healthcare by tackling the fundamental causes of uncommon disorders, leading to superior patient outcomes and less dependence on symptom-focused care. A case in point is Novotech, an Australian biotech firm, which reported in March 2024 that 43% of the 217 FDA-endorsed oncology therapies in 2023 were precision oncology, with 78 utilizing DNA or NGS-detectable biomarkers. Consequently, the heightened focus on precision medicine is fueling growth in the rare disease genome editing market.

Rare Disease Genome Editing Market Segmentation And Category Breakdown

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

Rare Disease Genome Editing Market Trends: What Is Shaping Future Industry Growth?

Key players in the rare disease genome editing market are concentrating their efforts on creating advanced therapeutic platforms, including CRISPR-based gene editing systems, with the goal of improving treatment accuracy, boosting clinical results, and tackling genetic diseases that were once considered incurable. These CRISPR-based systems represent innovative tools capable of making precise alterations to the genome, enabling the repair of genetic abnormalities or the insertion of therapeutic genes within human cells. As an example, in December 2023, Vertex Pharmaceuticals Inc., a biopharmaceutical firm from the United States, joined forces with CRISPR Therapeutics Inc., an American biotechnology research company, and secured conditional marketing approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is intended for individuals aged 12 and older who suffer from sickle cell disease (SCD) with recurring vaso-occlusive crises, or transfusion-dependent beta thalassemia (TDT). Casgevy operates by modifying a patient’s hematopoietic stem cells to restore fetal hemoglobin production, thereby lessening or eradicating disease manifestations and offering a possible functional cure for these conditions.

Rare Disease Genome Editing Market Competitive Analysis Of Major Industry Participants

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Access The Complete Rare Disease Genome Editing Market Report:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Rare Disease Genome Editing Market Regional Analysis And Leading Geography

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Rare Disease Genome Editing Market Change Between 2026 And 2030?

The rare disease genome editing market has shown rapid expansion in recent years. This market is set to grow from $1.29 billion in 2025 to $1.51 billion in 2026, with a compound annual growth rate (CAGR) of 17.8%. The historical growth can be attributed to several factors including advancements in gene editing technologies, a rising identification of rare genetic mutations, increased funding for genomic research, early successes observed in gene therapy trials, and growing academic research initiatives.

The rare disease genome editing market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $2.88 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.5%. This growth during the forecast period is fueled by several factors, including heightened investment in curative therapies for rare diseases, the increasing embrace of precision medicine strategies, an expansion of clinical trials in genome editing, stronger regulatory backing for orphan drugs, and greater cooperation between biotechnology firms and healthcare providers. Key developments throughout this period encompass the wider acceptance of CRISPR-based treatments, a heightened emphasis on gene editing for monogenic disorders, the expanding application of personalized genome editing techniques, the development of sophisticated editing platforms, and improved integration of genomic data analytics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Are The Main Drivers Accelerating The Growth Of The Rare Disease Genome Editing Market?

The expanding emphasis on precision medicine is anticipated to drive the advancement of the rare disease genome editing market in the future. Precision medicine, a customized healthcare strategy, utilizes a patient’s genetic makeup, surroundings, and lifestyle to deliver more precise and impactful therapies. The heightened attention on precision medicine stems from progress in genomic sequencing and biomarker identification, which facilitate accurate detection and specialized treatments. The rare disease genome editing market contributes to precision medicine by allowing for the specific correction of genetic mutations, thereby enhancing the personalization and efficacy of treatments. This approach improves healthcare by tackling the fundamental cause of rare disorders, leading to better patient results and less dependence on managing symptoms alone. For instance, Novotech, an Australia-based biotechnology company, reported in March 2024 that in 2023, precision oncology treatments accounted for 43% of the 217 FDA-approved oncology therapies, with 78 of these incorporating DNA or NGS-detectable biomarkers. Consequently, the growing emphasis on precision medicine is fostering the expansion of the rare disease genome editing market.

How Is The Rare Disease Genome Editing Market Distributed Across Key Segments?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

Which Trends Are Guiding The Development Of The Rare Disease Genome Editing Market?

Leading companies within the rare disease genome editing market are concentrating on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, with the aim of enhancing treatment precision, improving patient outcomes, and addressing genetic diseases previously deemed incurable. CRISPR-based gene editing systems are innovative technologies that enable precise modifications to the genome, facilitating the correction of genetic defects or the introduction of therapeutic genes into cells. An illustrative case occurred in December 2023, when Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and secured conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is indicated for patients aged 12 and older who have sickle cell disease (SCD) with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy functions by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which subsequently reduces or eliminates disease symptoms and offers a potential functional cure for these conditions.

Which Industry Players Are Present In The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Access The Complete Rare Disease Genome Editing Market Report:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

What Is The Largest Regional Market In The Rare Disease Genome Editing Market?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Rare Disease Genome Editing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company

Genome Editing Or Genome Engineering Market Report 2026

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Rare Disease Genome Editing Market In 2026, And How Will Its Value Evolve By 2030?

The rare disease genome editing market size has experienced rapid growth in recent years. It is projected to expand from $1.29 billion in 2025 to $1.51 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.8%. This growth during the historical period is attributable to advancements in gene editing technologies, a rise in the identification of rare genetic mutations, increased funding for genomic research, early positive results from gene therapy trials, and expanding academic research initiatives.

The rare disease genome editing market size is projected to experience substantial growth over the next few years. It is forecast to expand to $2.88 billion by 2030, achieving a compound annual growth rate (CAGR) of 17.5%. This growth during the forecast period is fueled by escalating investment in curative rare disease therapies, the increasing embrace of precision medicine strategies, the expansion of clinical genome editing trials, growing regulatory support for orphan drugs, and increased collaboration between biotechnology companies and healthcare providers. Prominent trends for the upcoming period encompass the wider adoption of CRISPR-based therapeutics, a heightened focus on gene editing for monogenic disorders, the expanding utilization of personalized genome editing approaches, the development of advanced editing platforms, and enhanced integration of genomic data analytics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Significant Factors Are Influencing The Rare Disease Genome Editing Market Expansion?

An escalating emphasis on precision medicine is anticipated to drive expansion within the rare disease genome editing market moving ahead. This tailored healthcare strategy, known as precision medicine, leverages an individual’s genetics, environmental factors, and lifestyle choices to deliver more precise and impactful treatments. The rising prominence of precision medicine stems from progress in genomic sequencing and the identification of biomarkers, which facilitate accurate diagnosis and specialized treatments. The rare disease genome editing market supports precision medicine through its capacity to allow for the focused correction of genetic mutations, leading to more customized and efficacious therapies. This contributes to healthcare progress by tackling the fundamental origins of rare conditions, enhancing patient results, and lessening dependence on managing symptoms alone. For example, in March 2024, Novotech, a biotechnology firm based in Australia, reported that in 2023, 43% of the 217 FDA-approved oncology therapies qualified as precision oncology treatments, with 78 of these involving DNA or NGS-detectable biomarkers. Consequently, the growing attention on precision medicine is propelling the expansion of the rare disease genome editing market.

What Are The Main Segments Within The Rare Disease Genome Editing Market Segment Structure?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

What Trends Are Affecting The Direction Of The Rare Disease Genome Editing Market?

Leading companies within the rare disease genome editing market are concentrating on the creation of sophisticated therapeutic platforms, such as CRISPR-based gene editing systems, aiming to boost treatment accuracy, elevate patient outcomes, and tackle genetic conditions previously lacking cures. These innovative CRISPR-based gene editing systems represent technologies capable of precise genomic alterations, enabling the rectification of genetic flaws or the insertion of therapeutic genes into cells. A notable example occurred in December 2023, when US-based biopharmaceutical company Vertex Pharmaceuticals Inc., collaborating with US-based biotechnology research company CRISPR Therapeutics Inc., secured conditional marketing approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for their product, CASGEVY (exagamglogene autotemcel, exa-cel). This therapy is prescribed for individuals aged 12 and above who suffer from sickle cell disease (SCD) with recurring vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy functions by modifying a patient’s hematopoietic stem cells, thereby reactivating fetal hemoglobin production, which subsequently diminishes or eradicates disease symptoms and presents a potential functional cure for these ailments.

Who Are The Companies Participating In The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Get The Full Rare Disease Genome Editing Market Report:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Which Region Has The Greatest Market Share In The Rare Disease Genome Editing Market?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Rare Disease Genome Editing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company

Genome Editing Or Genome Engineering Market Report 2026

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Rare Disease Genome Editing Market In 2026, And How Will Its Value Evolve By 2030?

The rare disease genome editing market size has experienced rapid growth in recent years. It is projected to expand from $1.29 billion in 2025 to $1.51 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.8%. This growth during the historical period is attributable to advancements in gene editing technologies, a rise in the identification of rare genetic mutations, increased funding for genomic research, early positive results from gene therapy trials, and expanding academic research initiatives.

The rare disease genome editing market size is projected to experience substantial growth over the next few years. It is forecast to expand to $2.88 billion by 2030, achieving a compound annual growth rate (CAGR) of 17.5%. This growth during the forecast period is fueled by escalating investment in curative rare disease therapies, the increasing embrace of precision medicine strategies, the expansion of clinical genome editing trials, growing regulatory support for orphan drugs, and increased collaboration between biotechnology companies and healthcare providers. Prominent trends for the upcoming period encompass the wider adoption of CRISPR-based therapeutics, a heightened focus on gene editing for monogenic disorders, the expanding utilization of personalized genome editing approaches, the development of advanced editing platforms, and enhanced integration of genomic data analytics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Significant Factors Are Influencing The Rare Disease Genome Editing Market Expansion?

An escalating emphasis on precision medicine is anticipated to drive expansion within the rare disease genome editing market moving ahead. This tailored healthcare strategy, known as precision medicine, leverages an individual’s genetics, environmental factors, and lifestyle choices to deliver more precise and impactful treatments. The rising prominence of precision medicine stems from progress in genomic sequencing and the identification of biomarkers, which facilitate accurate diagnosis and specialized treatments. The rare disease genome editing market supports precision medicine through its capacity to allow for the focused correction of genetic mutations, leading to more customized and efficacious therapies. This contributes to healthcare progress by tackling the fundamental origins of rare conditions, enhancing patient results, and lessening dependence on managing symptoms alone. For example, in March 2024, Novotech, a biotechnology firm based in Australia, reported that in 2023, 43% of the 217 FDA-approved oncology therapies qualified as precision oncology treatments, with 78 of these involving DNA or NGS-detectable biomarkers. Consequently, the growing attention on precision medicine is propelling the expansion of the rare disease genome editing market.

What Are The Main Segments Within The Rare Disease Genome Editing Market Segment Structure?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

What Trends Are Affecting The Direction Of The Rare Disease Genome Editing Market?

Leading companies within the rare disease genome editing market are concentrating on the creation of sophisticated therapeutic platforms, such as CRISPR-based gene editing systems, aiming to boost treatment accuracy, elevate patient outcomes, and tackle genetic conditions previously lacking cures. These innovative CRISPR-based gene editing systems represent technologies capable of precise genomic alterations, enabling the rectification of genetic flaws or the insertion of therapeutic genes into cells. A notable example occurred in December 2023, when US-based biopharmaceutical company Vertex Pharmaceuticals Inc., collaborating with US-based biotechnology research company CRISPR Therapeutics Inc., secured conditional marketing approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for their product, CASGEVY (exagamglogene autotemcel, exa-cel). This therapy is prescribed for individuals aged 12 and above who suffer from sickle cell disease (SCD) with recurring vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy functions by modifying a patient’s hematopoietic stem cells, thereby reactivating fetal hemoglobin production, which subsequently diminishes or eradicates disease symptoms and presents a potential functional cure for these ailments.

Who Are The Companies Participating In The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Get The Full Rare Disease Genome Editing Market Report:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Which Region Has The Greatest Market Share In The Rare Disease Genome Editing Market?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Rare Disease Genome Editing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company

Genome Editing Or Genome Engineering Market Report 2026

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Rare Disease Genome Editing Market In 2026 And What Value Is Projected For 2030?

The rare disease genome editing market has seen significant expansion in recent years. Its valuation is anticipated to climb from $1.29 billion in 2025 to $1.51 billion in 2026, showing a compound annual growth rate (CAGR) of 17.8%. The observed growth over the past period is primarily due to advancements in gene editing technologies, a greater understanding of rare genetic mutations, increased funding for genomic research, promising early results from gene therapy trials, and a proliferation of academic research initiatives.

The rare disease genome editing market is projected to experience significant expansion over the upcoming years. This market is anticipated to reach $2.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.5%. This projected growth throughout the forecast period stems from several factors, including heightened investment in curative treatments for rare diseases, a growing embrace of precision medicine strategies, the expansion of clinical trials for genome editing, increasing regulatory backing for orphan drugs, and enhanced partnerships between biotechnology firms and healthcare providers. Key trends anticipated during this period involve the increasing uptake of CRISPR-based therapies, a heightened focus on gene editing specifically for monogenic disorders, the wider application of personalized genome editing methods, the expansion of sophisticated editing platforms, and improved integration of genomic data analytics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Key Drivers Are Influencing The Growth Of The Rare Disease Genome Editing Market?

The future expansion of the rare disease genome editing market is anticipated to be driven by the escalating emphasis on precision medicine. This tailored healthcare methodology, known as precision medicine, leverages an individual’s genetic makeup, environmental factors, and lifestyle choices to deliver more precise and impactful treatments. The heightened attention on precision medicine stems from advancements in genomic sequencing and the identification of biomarkers, which facilitate accurate diagnosis and the development of targeted therapies. The rare disease genome editing market plays a crucial role in advancing precision medicine through its capacity for precise correction of genetic mutations, thereby ensuring more personalized and efficacious treatments. This technology contributes to healthcare progress by tackling the fundamental causes of rare conditions, leading to enhanced patient results and a decreased dependence on managing symptoms alone. As an illustration, in March 2024, Novotech, an Australian biotechnology firm, reported that in 2023, 43% of the 217 oncology therapies sanctioned by the FDA were precision oncology treatments, with 78 of these integrating DNA or NGS-detectable biomarkers. Consequently, the expanding emphasis on precision medicine is a key factor propelling the growth of the rare disease genome editing market.

What Are The Key Segments Of The Rare Disease Genome Editing Market?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

What Key Trends Are Influencing The Development Of The Rare Disease Genome Editing Market?

Leading firms in the rare disease genome editing market are concentrating on creating sophisticated therapeutic platforms, such as CRISPR-based gene editing technologies, aimed at elevating treatment accuracy, bettering patient results, and tackling genetic ailments that were previously untreatable. These CRISPR-based systems represent novel technologies that facilitate exact alterations to the genome, enabling the correction of genetic flaws or the insertion of therapeutic genes into cellular structures. As an illustration, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical entity, collaborated with CRISPR Therapeutics Inc., a US-based biotechnology research firm, and obtained conditional marketing approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is prescribed for individuals aged 12 and above suffering from sickle cell disease (SCD) with recurrent vaso-occlusive crises, or transfusion-dependent beta thalassemia (TDT). Casgevy functions by modifying a patient’s hematopoietic stem cells to re-initiate fetal hemoglobin synthesis, thereby diminishing or eradicating disease manifestations and providing a potential functional remedy for these ailments.

Who Are The Leading Companies Operating In The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Read the full rare disease genome editing market report here:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Rare Disease Genome Editing Market?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Disease Genome Editing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28313&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company

Genome Editing Or Genome Engineering Market Report 2026

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the rare disease genome editing market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Rare Disease Genome Editing Market?

The rare disease genome editing market size has seen rapid expansion in recent years. This market is expected to expand from $1.29 billion in 2025 to $1.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.8%. The historical growth of this market is attributable to key factors such as advancements in gene editing technologies, a rise in the identification of rare genetic mutations, increased funding for genomic research, the initial success observed in gene therapy trials, and burgeoning academic research initiatives.

The rare disease genome editing market is projected to experience substantial expansion in the coming years, reaching $2.88 billion by 2030, driven by a compound annual growth rate (CAGR) of 17.5%. This growth throughout the forecast period is primarily attributed to increased investment in curative rare disease therapies, the rising adoption of precision medicine strategies, the expansion of clinical genome editing trials, growing regulatory support for orphan drugs, and heightened collaboration between biotech companies and healthcare providers. Significant trends expected during this period include the wider acceptance of CRISPR-based therapeutics, a sharpened focus on gene editing for monogenic disorders, the increasing application of personalized genome editing techniques, the development of advanced editing platforms, and improved integration of genomic data analytics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Drivers Are Supporting Technological Adoption In The Rare Disease Genome Editing Market?

The future expansion of the rare disease genome editing market is anticipated to be driven by the growing emphasis on precision medicine. This tailored healthcare method involves utilizing an individual’s genetic makeup, environmental factors, and lifestyle choices to deliver more precise and efficacious therapies. The heightened attention to precision medicine stems from progress in genomic sequencing and the identification of biomarkers, which facilitate accurate diagnoses and specific treatment strategies. The rare disease genome editing market plays a supportive role in precision medicine by allowing for the precise rectification of genetic mutations, thereby enhancing the personalization and efficacy of treatments. This approach contributes to healthcare advancement by tackling the underlying causes of rare conditions, leading to better patient outcomes and a decreased dependence on managing symptoms alone. As an illustration, in March 2024, Novotech, an Australia-based biotechnology company, reported that in 2023, 43% of the 217 FDA-approved oncology therapies qualified as precision oncology treatments, with 78 of these therapies incorporating DNA or NGS-detectable biomarkers. Consequently, the growing emphasis on precision medicine is serving as a catalyst for the expansion of the rare disease genome editing market.

Which Segments Are Contributing To The Growth Of The Rare Disease Genome Editing Market?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

Which Trends Are Shaping Activity Within The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are focusing on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, to enhance treatment precision, improve therapeutic outcomes, and address previously incurable genetic diseases. These CRISPR-based gene editing systems represent innovative technologies that enable precise modifications to the genome, allowing for the correction of genetic defects or the introduction of therapeutic genes into cells. For instance, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and received conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy works by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which reduces or eliminates disease symptoms and offers a potential functional cure for these conditions.

Who Are The Top-Performing Companies In The Rare Disease Genome Editing Market In Recent Years?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Which Region Currently Holds The Largest Share Of The Rare Disease Genome Editing Market?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Rare Disease Genome Editing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28313&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company

Genome Editing Or Genome Engineering Market Report 2026

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the rare disease genome editing market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Rare Disease Genome Editing Market?

The rare disease genome editing market size has seen rapid expansion in recent years. This market is expected to expand from $1.29 billion in 2025 to $1.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.8%. The historical growth of this market is attributable to key factors such as advancements in gene editing technologies, a rise in the identification of rare genetic mutations, increased funding for genomic research, the initial success observed in gene therapy trials, and burgeoning academic research initiatives.

The rare disease genome editing market is projected to experience substantial expansion in the coming years, reaching $2.88 billion by 2030, driven by a compound annual growth rate (CAGR) of 17.5%. This growth throughout the forecast period is primarily attributed to increased investment in curative rare disease therapies, the rising adoption of precision medicine strategies, the expansion of clinical genome editing trials, growing regulatory support for orphan drugs, and heightened collaboration between biotech companies and healthcare providers. Significant trends expected during this period include the wider acceptance of CRISPR-based therapeutics, a sharpened focus on gene editing for monogenic disorders, the increasing application of personalized genome editing techniques, the development of advanced editing platforms, and improved integration of genomic data analytics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Drivers Are Supporting Technological Adoption In The Rare Disease Genome Editing Market?

The future expansion of the rare disease genome editing market is anticipated to be driven by the growing emphasis on precision medicine. This tailored healthcare method involves utilizing an individual’s genetic makeup, environmental factors, and lifestyle choices to deliver more precise and efficacious therapies. The heightened attention to precision medicine stems from progress in genomic sequencing and the identification of biomarkers, which facilitate accurate diagnoses and specific treatment strategies. The rare disease genome editing market plays a supportive role in precision medicine by allowing for the precise rectification of genetic mutations, thereby enhancing the personalization and efficacy of treatments. This approach contributes to healthcare advancement by tackling the underlying causes of rare conditions, leading to better patient outcomes and a decreased dependence on managing symptoms alone. As an illustration, in March 2024, Novotech, an Australia-based biotechnology company, reported that in 2023, 43% of the 217 FDA-approved oncology therapies qualified as precision oncology treatments, with 78 of these therapies incorporating DNA or NGS-detectable biomarkers. Consequently, the growing emphasis on precision medicine is serving as a catalyst for the expansion of the rare disease genome editing market.

Which Segments Are Contributing To The Growth Of The Rare Disease Genome Editing Market?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

Which Trends Are Shaping Activity Within The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are focusing on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, to enhance treatment precision, improve therapeutic outcomes, and address previously incurable genetic diseases. These CRISPR-based gene editing systems represent innovative technologies that enable precise modifications to the genome, allowing for the correction of genetic defects or the introduction of therapeutic genes into cells. For instance, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and received conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy works by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which reduces or eliminates disease symptoms and offers a potential functional cure for these conditions.

Who Are The Top-Performing Companies In The Rare Disease Genome Editing Market In Recent Years?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Which Region Currently Holds The Largest Share Of The Rare Disease Genome Editing Market?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Rare Disease Genome Editing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28313&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company

Genome Editing Or Genome Engineering Market Report 2026

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Rare Disease Genome Editing Industry In 2025?

The market for rare disease genome editing has experienced rapid expansion in recent years. It is forecast to increase from $1.09 billion in 2024 to $1.29 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.9%. The market’s growth during the historical period was driven by increasing government funding for genetic research, a rising awareness of rare disease diagnosis, enhanced collaboration among biotech companies, and a surge in investment in personalized medicine.

The rare disease genome editing market size is projected to experience substantial growth in the coming years. Its value is expected to reach $2.46 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 17.6%. This expansion throughout the forecast period can be attributed to the increasing incorporation of AI in genome editing, a rising demand for targeted therapies, ongoing advancements in gene delivery systems, the growing prevalence of multi-gene disorders, and an increased emphasis on pediatric rare diseases. Noteworthy trends for the forecast period include enhancements in multi-gene editing techniques, the integration of AI-driven genomic analysis, personalized gene therapies facilitated by technology, developments in in vivo gene delivery systems, and progress in high-throughput genome screening.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Rare Disease Genome Editing Industry?

The expanding emphasis on precision medicine is projected to drive the growth of the rare disease genome editing market in the coming years. Precision medicine involves customizing prevention, diagnosis, and treatment based on an individual’s unique genetic composition, environmental factors, and lifestyle. This tailored healthcare strategy leverages a patient’s genetics, surroundings, and habits to deliver more precise and efficacious treatments. The heightened attention to precision medicine stems from breakthroughs in genomic sequencing and the identification of biomarkers, which facilitate accurate detection and targeted interventions. The rare disease genome editing market aids precision medicine by allowing for the specific correction of genetic mutations, thereby making therapies more individualized and effective. It enhances healthcare by tackling the fundamental cause of rare conditions, leading to better patient outcomes and lessening dependence on managing symptoms. For instance, in March 2024, Novotech, an Australia-based biotechnology company, in 2023, 43% of the 217 FDA-approved oncology therapies were precision oncology treatments, with 78 incorporating DNA or NGS-detectable biomarkers. Consequently, the rising focus on precision medicine is propelling the growth of the rare disease genome editing market.

How Is The Rare Disease Genome Editing Market Classified Into Different Segments?

The rare disease genome editing market covered in this report is segmented as

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

Which Ongoing Trends Are Expected To Shape The Rare Disease Genome Editing Market Outlook?

Leading companies within the rare disease genome editing market are concentrating on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, with the goal of enhancing treatment precision, improving therapeutic outcomes, and addressing genetic diseases previously deemed incurable. These CRISPR-based gene editing systems are innovative technologies designed to enable precise modifications to the genome, allowing for the correction of genetic defects or the introduction of therapeutic genes into cells. As an example, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and obtained conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This therapy is indicated for patients aged 12 and older with sickle cell disease (SCD) experiencing recurrent vaso-occlusive crises or with transfusion-dependent beta thalassemia (TDT). Casgevy operates by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, a process that reduces or eliminates disease symptoms and offers a potential functional cure for these conditions.

Who Are The Prominent Global Companies Shaping The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., and MeiraGTx Holdings plc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

How Do Regional Market Performances Compare Within The Rare Disease Genome Editing Industry?

North America was the largest region in the rare disease genome editing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare disease genome editing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Rare Disease Genome Editing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28313&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2025, By The Business Research Company

Genome Editing Or Genome Engineering Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model